Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Regulus Therapeutics Inc is a biotechnology business based in the US. Regulus Therapeutics shares (RGLS) are listed on the NASDAQ and all prices are listed in US Dollars. Regulus Therapeutics employs 25 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.10 |
|---|---|
| 52-week range | $0.16 - $0.89 |
| 50-day moving average | $0.24 |
| 200-day moving average | $0.35 |
| Wall St. target price | $1.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.28 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.1 from 2022-06-29
| 1 week (2022-06-24) | 772.82% |
|---|---|
| 1 month (2022-05-28) | N/A |
| 3 months (2022-04-01) | 545.96% |
| 6 months (2021-12-29) | 552.99% |
| 1 year (2021-07-01) | 154.39% |
|---|---|
| 2 years (2020-07-01) | 195.77% |
| 3 years (2019-07-01) | 52.17% |
| 5 years (2017-06-30) | 113.07% |
| Revenue TTM | $5 million |
|---|---|
| Gross profit TTM | $-17,794,000 |
| Return on assets TTM | -35.44% |
| Return on equity TTM | -74.69% |
| Profit margin | 0% |
| Book value | $0.34 |
| Market capitalisation | $35.1 million |
TTM: trailing 12 months
We're not expecting Regulus Therapeutics to pay a dividend over the next 12 months.
Regulus Therapeutics's shares were split on a 1:12 basis on 3 October 2018. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Regulus Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Regulus Therapeutics shares which in turn could have impacted Regulus Therapeutics's share price.
Over the last 12 months, Regulus Therapeutics's shares have ranged in value from as little as $0.16 up to $0.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regulus Therapeutics's is 2.167. This would suggest that Regulus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Regulus Therapeutics Inc. , a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.